Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 3/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 3/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.38 |
| ▸ | DPP4 | P27487 | 5/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12025066 | 0.88 | BTK (0.40) | SYKBTKJAK3EGFRLCK | |
| SCHEMBL12025081 | 0.78 | BTK (0.44) | SYKBTKJAK3MAP4K4AURKA | |
| SCHEMBL173652 | 0.73 | ALDH1A1 (0.38) | BTK | |
| SCHEMBL2490832 | 0.71 | BTK (0.47) | SYKBTKJAK3EGFRLCK | |
| SCHEMBL2490830 | 0.71 | BTK (0.47) | SYKBTKJAK3EGFRLCK | |
| SCHEMBL12045171 | 0.68 | SYK (0.44) | SYKBTKJAK3EGFRLCK | |
| SCHEMBL2490136 | 0.66 | BTK (0.46) | SYKBTK | |
| SCHEMBL30599827 | 0.66 | MET (0.43) | BTKJAK3RETPDE10A | |
| SCHEMBL14800060 | 0.66 | MAP4K4 (0.40) | BTKJAK3MAP4K4AURKAPDPK1 | |
| SCHEMBL14800059 | 0.66 | MAP4K4 (0.40) | BTKJAK3MAP4K4AURKAPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2010056875-A1 | PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, LCK | SYK 2/4885BTK 1/4885JAK3 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.